Primary Job Title Vice President of R&D and Co-founder Primary Organization Pheon Therapeutics
Location Harpenden, Hertford, United Kingdom Regions Europe, Middle East, and Africa (EMEA) Gender Male
LinkedIn View on LinkedIn
Paul Jackson is a Co-founder and the VP of R&D at Pheon Therapeutics. He has over 10 years of experience in the Antibody-Drug Conjugate field, initially in the design/discovery of small molecule payloads and subsequently pre-clinical development of ADCs. Paul is an inventor of 28 patent applications and has published 15 papers in the
field.
After completing undergraduate and post-graduate degrees in pharmaceutical sciences and bioinformatics at LJMU and the University of Liverpool, Dr. Jackson earned his Ph.D. in the laboratory of Prof. David Thurston at King’s College London, where he developed in silico molecular dynamics-based methods for the design of sequence-selective DNA-interactive ADC payloads. Dr. Jackson then carried out postdoctoral research at King’s College, utilizing methods developed in his doctoral studies to design new classes of ADC payloads, and co-founded Pheon Therapeutics, (previously Femtogenix) to commercialize the newly developed agents. Paul led Pheon Therapeutics’ operations from its foundation in 2015, leading R&D on a day-to-day basis and business development activities. Paul has experience in negotiating and closing licensing agreements, alliance management, and corporate development.
